The present study was conducted on a series of 41 Egyptian children with newly diagnosed acute lymphoblastic leukemia (ALL) to investigate TEL and AML1 abnormalities. The TEL-AML1 fusion was observed in six patients both by RT-PCR and FISH analyses, with a frequency of 22.2% among the B-lineage group, whereas TEL deletion was seen by FISH analysis in seven patients (17.1%). By FISH analysis, nine patients (22%) showed evidence of extra AML1 copies. In five of these patients the extra copies were due to non-constitutional trisomy 21, whereas in the remaining four cases they were due to tandem AML1 copies on der(21), as evidenced by metaphase FISH. Unexpectedly however, enhanced AML1 expression levels were seen by real-time quantitative RT-PCR in 18 out of the 41 ALL patients (43.9%). This high level of AML1 expression could be an important factor contributing to the pathogenesis and progression of childhood ALL. One key mechanism for overexpression seems to be the extra copies of AML1, but other mechanisms may involve an alteration of the activity of the AML1 promoter. Here, we also report two novel findings. The first is an intragenic deletion of TEL exon 7 in a case of T cell ALL. This deletion creates a frame-shift and results in a truncated protein lacking the C-terminus that includes the ETS domain. This shorter TEL is presumably unable to bind DNA. The second finding is a rearrangement of AML1 in a case of T cell ALL due to t(4;21)(q31;q22). This is the first reported chromosomal translocation where AML1 is rearranged in childhood T cell ALL. Leukemia (2002) 16, 658-668.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood. 1 Differences in the relative frequency of the subtypes of childhood ALL in different geographical areas have been well documented. 2 The diagnosis of ALL is based on morphologic features and on cytochemical and immunophenotypic studies of the leukemic blast cells. 3 Genetic abnormalities defined by karyotyping and molecular analysis have important clinical and biologic significance in childhood ALL. Approximately 25% of childhood ALL cases have specific cytogenetic abnormalities (not including changes in ploidy), some of which confer a poor prognosis. 4 To date, the cryptic t(12;21)(p13;q22) is the most frequent genetic abnormality in childhood ALL, with a frequency ranging from 18% to 32% of B-lineage ALL. [5] [6] [7] [8] [9] The genes altered by the t(12;21), TEL and AML1, are the most common targets of chromosomal rearrangements in human leukemias, and are fused to a wide range of partner genes in both myeloid and lymphoid leukemias. 5, 10 The TEL gene (also known as ETV6), located in the chromosome band 12p13, encodes a member of the ETS family of transcription factors, characterized by a C-terminus DNA-binding domain referred to as the ETS domain, 11, 12 and by an N-terminus helix-loop-helix (HLH) domain called the pointed domain, which mediates homotypic oligomerization. 13, 14 The AML1 gene (also known as RUNX1 or CBFA2), located in the chromosome band 21q22, is the other target of the t (12;21) . AML1 encodes a transcription factor that binds the sequence TGT/cGGT.
15,16 AML1 DNA-binding affinity is increased through heterodimerization with the CBF␤ protein forming a complex called human core binding factor (CBF). Both the DNA-binding and the interaction with CBF␤ are mediated through the N-terminus domain of AML1 that is highly homologous to the Drosophila RUNT domain. 17, 18 The DNA-binding activity of CBF is critical for the tissue-specific expression of several hematopoietic-specific genes. AML1 also has a C-terminus transactivation domain (TA). 15 Cloning and molecular analysis of the t(12;21) breakpoint demonstrated that this translocation disrupts TEL just upstream of its ETS domain at nucleotide-1033. In very few cases, the breakpoint occurred at a more 5Ј site corresponding to the site of fusion described for TEL-PDGFR␤ at nucleotide-487. Both breakpoints fuse TEL to nearly all of AML1, including its RUNT and TA domains. 5, 19, 20 Expression of the TEL-AML1 chimeric gene is driven by the TEL promoter, and the fusion protein directly functions as a constitutive transcriptional repressor. [21] [22] [23] A significant subset of TEL-AML1 patients lose the untranslocated TEL allele, suggesting that loss of the normal TEL directly contributes to the progress of neoplastic transformation. 24 In addition, not all childhood ALL patients with loss of TEL carry the TEL-AML1 fusion. 25, 26 Recently published data link haploinsufficiency of AML1 with a form of familial platelet disorder with predisposition to acute myeloid leukemia (AML). 27 Furthermore, point mutations in AML1 have been reported in AML and chronic myeloid leukemia, resulting in a defective function of the protein, 28 whereas tandem amplification of AML1 was observed in a number of cases of childhood ALL. [29] [30] [31] Moreover, an increased incidence of AML and ALL is seen in patients who have an increased dose of AML1 as a result of Down's syndrome (trisomy 21). 32 Taken together, these reports strongly suggest that the level of expression of AML1 is crucial for hematopoeitic differentiation, and that over-expression or haploinsufficiency of AML1 may play an etiologic role in human leukemia.
In the present study, we report our results on the frequency of TEL and AML1 rearrangements and the level of AML1 expression in a group of Egyptian children with ALL. Our results show that in this group the frequency of childhood T cell ALL is higher than that reported for western countries, 33 whereas the frequency of TEL-AML1 fusion is comparable to western countries among the B-lineage group. [5] [6] [7] More importantly however, we found that AML1 is over-expressed in over 40% of childhood ALL. Thus this study indicates that, in contrast to myeloid leukemia, the enhanced expression of AML1 could be an important factor contributing to the pathogenesis and progression of ALL.
Materials and methods

Patient and control samples
Between January 1999 and May 2000, 41 children were diagnosed with ALL at the Clinical Pathology Department of Alexandria University Hospital, Alexandria, Egypt. All patients were classified morphologically and immunologically. 33, 34 All bone marrow (BM) samples contained at least 85% blast cells. Peripheral blood (PB) and BM mononuclear cells were isolated by means of gradient centrifugation over Ficoll and were used for the immunophenotypic studies. Remaining samples were stored frozen at −196°C in freezing medium with 10% DMSO (Life Technologies, Rockville, MD, USA). PB samples were also collected from 10 healthy children to be used as negative controls for FISH and RT-PCR studies. An informed consent was given by the parents.
Immunophenotypic studies
PB or BM blast cells were tested with a panel of 12 monoclonal antibodies (MoAbs) (DAKO, Glostrup, Denmark) against B-and T-lymphoid and myeloid-associated antigens to complement the immunological classification. These included: CD2, cytoplasmic CD3, CD7, CD10, CD13, CD14, CD19, cytoplasmic CD22, CD33, CD34, cytoplasmic chain, and surface Ig. The indirect single immunofluorescence staining technique was employed before the cells were analyzed by flow cytometry. B-lineage ALL cases were categorized into: early pre-B ALL (cytoplasmic CD22-positive, cytoplasmic chain-negative), pre-B ALL (cytoplasmic chain-positive, surface Ig-negative), and B cell ALL (surface Ig-positive). 33 
Cytogenetic studies
Direct as well as short-term (24 and 48 h) cultures were performed from the patients' BM and/or PB mononuclear cells without a stimulating agent in RPMI 1640 medium supplemented with 20% fetal calf serum, L-glutamine and antibiotics. As for the healthy controls, a phytohaemagglutinin stimulated short-term (72 h) culture was done from the PB mononuclear cells. Chromosome preparations were made in a standard manner and banded by Trypsin-Giemsa. The chromosomes were analyzed, and the karyotype described according to the International System for Human Cytogenetic Nomenclature (ISCN 1995). 35 The remaining fixed cell pellets and/or unstained metaphase slides were stored at −20°C for further FISH studies.
FISH analysis
FISH analyses were performed on the 41 ALL samples and the 10 control samples using cells stored in fixative and/or unstained metaphase slides. We used spectrum green-and spectrum red-conjugated dual-color DNA probes specific for the TEL and AML1 genes (Vysis, Downers Grove, IL, USA).
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Hybridization and washes were performed according to the manufacturer's instructions except for the addition of a slide pre-treatment step with RNaseA and Pepsin. The slides were then counterstained with DAPI. The TEL probe (green) spans 350 kb, and includes mostly the telomeric part of the gene that translocates to der (21) in the t(12;21), and therefore does not appear split in FISH analysis. The AML1 probe (red) spans 500 kb, and includes both the telomeric and centromeric regions of the gene, and is therefore split in the t(12;21).
The hybridized slides were analyzed with an Axioskop microscope (Zeiss, Hallbergmoos, Germany) coupled to a PSI imaging system with MacProbe 3.4 software, using a cooled charge-coupled device (CCD) camera (Photometrics, Tucson, AZ, USA). At least 100 interphase nuclei and/or metaphases were scored for each patient and 200 for each control. In interphase nuclei with t(12;21), TEL-AML1 fusion appeared as a yellow signal (fused green and red signals). Extra copies of AML1 were considered positive for those interphase nuclei with more than two red signals, provided that the signals were equal in intensity and were separated. The cut-off values of positivity for TEL-AML1 fusion, TEL deletion and AML1 extra copies were defined as the mean of control cases plus three standard deviations (s.d.). For patient No. 32, metaphase FISH analyses were performed with TEL-AML1 dual-color probes together with whole chromosome paint spectrum green probes for chromosome 4 and 7 (Vysis).
RT-PCR studies
Total RNA was extracted from cryopreserved unstimulated BM mononuclear cells, using TRIzol reagent (Life Technologies) following the manufacturer's protocol. RNA was treated with amplification grade DNase I to eliminate any residual genomic DNA from the sample (Life Technologies). cDNA was synthesized from 2.0 g of total RNA using M-MuLV reverse transcriptase and random hexamer primers (MBI Fermentas, Hanover, MD, USA). For the PCR reaction, a 2 l aliquot from the completed RT reaction mix was added to a new PCR tube containing a final reagent concentration of 1× PCR Red Taq Buffer (Sigma, St Louis, MO, USA), 125 M each of dATP, dCTP, dGTP, dTTP, 330 nM of each primer, 0.05 U/l Red Taq DNA polymerase (Sigma) and water for a final volume of 15 l.
To amplify the TEL-AML1 fusion transcript, primer set 1 (TEL-874F: AML1-146R) and primer set 2 (TEL-370F: AML1-146R) were used, to detect both the common and the rare TEL breakpoints. The normal TEL and AML1 messages on the untranslocated chromosomes were amplified, as an internal control in all cases, using primer set 3 (TEL-874F: TEL-1339R) and primer set 4 (AML1-519F: AML1-783R) respectively ( Figure 1 and Table 1 ). Forty cycles of PCR (94°C for 40 s, 64°C for 40 s and 72°C for 1 min) were performed, and 10 l aliquots of the PCR product were electrophoresed on a 1.5% agarose gel.
Cloning and sequencing of PCR products
By RT-PCR analysis, case No. 35 showed two TEL PCR products, one of the expected size (487-bp) and another shorter product. This shorter TEL PCR product was cut out of the gel, purified using the QIAquick gel extraction kit (Qiagen, Valencia, CA, USA), cloned into pCR4-TOPO plasmid vector using TA cloning (Invitrogen, Carlsbad, CA, USA), and sequenced 
Table 1
Primer sets used for RT-PCR
Set 1 TEL-874F 5Ј-TCC GTG GAT TTC AAA CAG TCC A-3Ј AML1-146R 5Ј-AAC GCC TCG CTC ATC TTG CCT G-3Ј Set 2 TEL-370F 5Ј-CTC CTT CAG CAT ATT CTG AAG C-3Ј AM1-146R 5Ј-AAC GCC TCG CTC ATC TTG CCT G-3Ј Set 3 TEL-874F 5Ј-TCC GTG GAT TTC AAA CAG TCC A-3Ј TEL-1339R 5Ј-TTT GTT CAT CCA GCT CCT GGG A-3Ј
Set 4 AML1-519F 5Ј-CAC TCT GAC CAT CAC TGT CTT C-3Ј AML1-783R 5Ј-CTG CAT CTG ACT CTG AGG CTG A-3Ј using fmol DNA sequencing system (Promega, Madison, WI, USA). ␥-
35
S-dATP was used in a one step labeling and primer extension/chain termination reaction. The insert was sequenced in both directions using the T 3 and T 7 primers. Five l of each reaction were run through 6% high-resolution denaturing gel. The gel was dried, exposed to an X-ray film for 24 h, developed and analyzed.
Real-time quantitative RT-PCR for AML1
To construct the standard curves, total RNA was extracted from the NB-4 cell line, and cDNA was synthesized from 2.0 g of total RNA. The cDNA was serially diluted (1:5) in DNase-RNase-free water (50 ng/l to 0.016 ng/l). Real-time quantitative PCR analysis was performed using the TaqMan PCR Core Reagent Kit (Applied Biosystems, Foster City, CA, USA) in a 50 l reaction containing 2 l of cDNA, 1× Taqman Buffer A, 5 mM MgCl 2 , 200 M dATP, 200 M dCTP, 200 M dGTP, 400 M dUTP, 0.01 U/l AmpErase uracil-N-glycosylase (UNG), 0.025 U/l AmpliTaq Gold DNA polymerase, 200 nM forward and reverse primers and 100 nM TaqMan probe. The thermal cycling conditions were: 2 min at 50°C for activation of AmpErase UNG, 10 min at 95°C for the activation of AmpliTaq Gold DNA polymerase and 40 cycles of 95°C for 15 s and 60°C for 1 min for PCR amplification. In order to correct for differences in the amount of total cDNA added to a reaction, we used a house keeping gene, GAPDH, as an internal reference.
TaqMan probes were labeled at the 5Ј end with the reporter dye molecule FAM (6-carboxy-fluorescein), and at the 3Ј end with the quencher dye molecule TAMRA (6-carboxy-tetramethyl-rhodamine). AML1 primers and probe were designed in the 5Ј region of the TA domain, using the Primer Express Software (Applied Biosystems) ( Figure 1 ). These were AML1-828F (5Ј-CCC ACC GTG GTC CTA CGA T-3Ј), AML1-905R (5Ј-CTG GCA CGT CCA GGT GAA A-3Ј), and AML1-probe (5Ј-6FAM-TCC TTC TGT GCA CCC AGC AAC GC-TAMRA-3Ј). The GAPDH primers and probe were adopted from Applied Biosystems.
The standard curves included six points at a final RNA concentration ranging from 100 ng to 0.032 ng, whereas for the patient and control samples 25 ng were examined. The GAPDH and AML1 expression in these samples was related to the corresponding standard curve as the number of nanograms of NB-4 cell line RNA with the same level of expression. A standard curve as well as a non-template negative control were included with each run and the standard points were run in triplicate. The patient and control samples were tested in duplicate in two separate runs, and the average value for all four reactions was used for quantification. When disagreement was observed between the four reactions, the sample was retested.
Real-Time PCR amplification was performed on the iCycler iQ Real-Time detection system (Bio-Rad, Hercules, CA, USA), and the data were collected and analyzed using the iCycler iQ v2.1 software. The corrected AML1 expression level was defined as the AML1 expression level divided by the GAPDH expression level.
Results
Immunophenotypic subtypes of childhood ALL in Egypt
Between January 1999 and May 2000, 41 children between 5 months and 12 years of age were diagnosed with ALL at the Clinical Pathology Department of Alexandria University Hospital. This group of patients is relatively small in number, but it represents the Egyptian childhood population, as it includes patients from different socio-economic classes from all over the city of Alexandria. Our group of patients was designed to include patients from newborn to 17 years of age. Possibly because of the high incidence of childhood ALL between the ages of 1 and 5 years, 36 our group had no child older than 12 years at diagnosis. Relevant clinical and immunophenotypic data of this group of patients are included in Table 2 .
Blast cells were tested with a panel of 12 monoclonal antibodies against B-and T-lymphoid and myeloid-associated antigens. This immunophenotypic analysis revealed 15 cases (36.6%) with early pre-B ALL (10 cases CD10-positive and the rest were negative), 11 cases (26.8%) with pre-B ALL (All CD10-positive), one case (2.4%) with B cell ALL (CD10-negative), and 14 cases (34.2%) with T cell ALL (all CD10-negative). The frequency of T cell ALL in the present study was significantly higher than that reported for western countries. 33 
Cytogenetic and FISH studies Conventional cytogenetics:
Among the 41 ALL cases, 36 (87.8%) were successfully cytogenetically analyzed. In the , short TEL allele with an internal deletion of exon 7 leading to an out of frame transcript and loss of the ETS domain; T, non-constitutional trisomy 21; a , cases that were not included in the group with tandem AML1 copies because the percentages of cells with extra copies of AML1 were below our calculated cut-off value; QRT-PCR, real time quantitative RT-PCR. Patients with corrected AML1 expression level significantly higher than the mean of the control group (P value Ͻ0.05) were listed in bold type in the last column.
five remaining cases, no metaphase spreads could be detected. The immunophenotypes, karyotypes and FISH analysis results are shown in Table 2 .
In total, 13 cases (31.7%) had normal karyotype, five (12.2%) were hypodiploid, seven (17.1%) were pseudodiploid, and 12 (29.3%) were hyperdiploid. The most common structural chromosomal abnormalities were: t(4;11)(q21;q23) in two cases (4.9%), t(1;19)(q23;p13) in one case (2.4%), t(9;22)(q34;q11) in one case (2.4%), t(8;14)(q24;q32) in one case (2.4%) and t(11;14)(p13;q11) in one case (2.4%). Overall, these abnormalities were seen with a frequency similar to that reported for other studies of childhood ALL. 37, 38 Patient No. 32 had a translocation between chromosome 4 and 21, t(4;21)(q31;q22), associated with a del(7)(q22), in 19 of 20 metaphases examined (Figure 2 ).
TEL-AML1 fusion and TEL deletion:
FISH analyses were performed on the 41 ALL and 10 control samples using dualcolor DNA probes specific for TEL and AML1. The cut-off value of positivity for TEL-AML1 fusion was 9.5%, whereas for TEL deletion it was 5.1%. Six patients (14.6%) showed TEL-AML1 fusion (Figure 3a and b) . The percentage of positive cells ranged from 24% to 100% (mean = 58%). All these patients were between the age of 2 and 6 years with a total leukocyte count (TLC) that ranged between 7.1 and 78.8 × 10 3 /l. Two of them had early pre-B ALL and the remaining four had pre-B ALL. All of them were CD10-positive. Four patients had normal karyotype, however, in the two remaining patients no metaphases could be detected.
Deletion of one TEL allele was observed by FISH analysis in seven patients (17.1%) (Figure 3b and c) . Two of these patients had T cell ALL. The other five patients had B-lineage ALL, two of them also had a t(12;21) (patient Nos 3 and 4). Finally, one early pre-B ALL patient (No. 27) had a t(9;22)(q34;q11) associated with a translocation between chromosome 3 and chromosome 12, t(3;12)(p21;p13), with deletion of the TEL allele on the der(12). Because our TEL probe does not span the entire gene, it was unclear whether TEL was involved in the 12p13 breakpoint or not. (Table 2) , showed a normal AML1 signal on the intact chromosome 21 and 2 small signals, one on der(21) and the other on der(4), in 16 metaphases and in 89% of the interphase cells ( Figure  3d and e). The t(4;21)(q31;q22) was confirmed using the chromosome 4 paint-probe together with the TEL-AML1 dual-color probes. The results showed that one chromosome 4 was painted end-to-end whereas both derivative chromosomes 4 and 21 were partially painted, and that the split AML1 red signal was on derivative chromosomes 4 and 21 (Figure 3f ). On the other hand, the chromosome 7 paint-probe together with the TEL-AML1 dual-color probes confirmed the del(7)(q22), with no chromosome 7 material either on der(21) or on der(4) (Figure 3g ). This is the first reported translocation that rearranges AML1 in childhood T cell ALL. The results of the FISH analysis indicate that the AML1 is split most probably in the middle, in contrast to what was observed for the t(12;21) in childhood B-lineage ALL. 20 Unfortunately, because of the lack of available material, a detailed molecular analysis of this translocation breakpoint is not possible at the present time. For the same reason, we also do not know whether this translocation leads to the expression of an AML1 fusion gene.
AML1 extra copies:
Our calculated cut-off value of positivity for extra copies of AML1 was 7.3%. In our group of patients, nine out of the 41 cases (22%) showed either three or four copies of AML1 by FISH analysis (Figure 3h and i) . The percentage of the cells with AML1 extra copies, ranged from 10% to 91% (mean = 52%). In five of these patients, the origin of the gain was non-constitutional trisomy 21 in the malignant cells. In the four remaining patients (all of whom have B-lineage ALL) the AML1 extra copies were due to tandem repeats of the gene on chromosome band 21q22, as evidenced by metaphase FISH (Figure 3j and k) . Three of these four patients (Nos 1, 23 and 41) had a normal karyotype by conventional cytogenetics, whereas the fourth patient (No. 31) had a subpopulation of cells with monosomy 19. In all four patients, chromosome 21 appeared normal by conventional (Nos 4, 17, 20, 26, 27 and 39) , between 3% and 6% of the cells showed at least one extra copy of AML1 gene. These patients were not included in the group with tandem AML1 copies because the percentages of the cells with extra copies were below our calculated cut-off value. All of the patients with tandem AML1 copies had no evidence of trisomy 21 by conventional cytogenetics.
RT-PCR studies and sequencing TEL-AML1 fusion:
To confirm the TEL-AML1 fusion, RT-PCR analysis was performed for all 41 patients using two sets of primers, set 1 and 2 (Table 1) . Primer set 1 (TEL-874F: AML1-146R) generated the expected 269-bp TEL-AML1 band in six samples (14.6%), indicating fusion of TEL exon 5 to exon 2 of AML1. PCR amplification of the samples with primer set 2 (TEL-370F: AML1-146R) did not produce any obvious band, confirming that the breakpoint in all t(12;21) samples was at the distal frequent site upstream of the ETS region. 19, 20 Concordant results were observed by FISH analysis (Table 2) .
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A novel intragenic deletion in TEL:
As a control for TEL-AML1 analysis, PCR analysis was also performed with primers specific for either TEL (primer set 3) or AML1 (primer set 4) ( Table 1 ). Whereas we did not observe any abnormal sized band for AML1 (data not shown), in one of the samples (No. 35), we detected two different TEL-specific products: one had the expected size (487-bp) and the second one was shorter (about 100-bp shorter). Cloning and sequencing of this shorter PCR product showed that an intragenic deletion of TEL exon 7 (111-bp) 39 had occurred (Figure 4 ), leading to an out of frame transcript and to the predicted loss of the C-terminus including the ETS domain in the translated protein. This shorter TEL is presumably unable to bind the DNA. Thus it appears that TEL could also be functionally inactivated by a specific internal deletion.
Real-time quantification of AML1 expression
For this assay, we used normal PB mononuclear cells as controls. Although these PB mononuclear cells are not the ideal reference for these studies, we should point out that obtaining a sample of immature B or T cells from a normal healthy child is practically impossible, and our control samples were the best available choice. We did not use normal BM samples as controls because they include mostly myeloid and erythroid lineage cells and we are concerned with the lymphoid lineage cells. FISH analyses using spectrum green-and spectrum red-conjugated dual-color DNA probes specific for TEL and AML1 genes. The TEL probe (green) includes mostly the telomeric part of the gene that translocates to der(21) in the t(12;21), and therefore does not appear split in FISH analysis. The AML1 probe (red) includes both the telomeric and centromeric regions of the gene, and is therefore split in the t(12;21). (21) (arrowhead) and the other on the der(4) (arrow). (f) Metaphase FISH (case No. 32) using TEL-AML1 dual-color probes together with whole chromosome 4 spectrum green paint-probe. One small AML1 signal (red) can be seen on der(21) (arrowhead) and the other one on der(4) (arrow). The intact chromosome 4 can be seen painted end-to-end, while both der(4) and der(21) are partially painted. (g) Metaphase FISH (case No. 32) using TEL-AML1 dual-color probes together with whole chromosome 7 spectrum green paint-probe. A chromosome 7 deletion can be seen (dashed arrow), with no chromosome 7 material either on der(21) (arrowhead) or on der (4) 
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PCR amplification and standard curves:
The PCR amplification curve of serially diluted (1:5) NB-4 cell line cDNA amplified with AML1 primers is shown in Figure 5a , in which the changes in the fluorescence signal of the reporter dye (RFU) are plotted on the Y axis and the cycle number on the X axis. The amplification plots shifted to the right as the input RNA was reduced. A similar curve was constructed for GAPDH. In this system the threshold cycle (C T ) was defined as the cycle number at which the RFU of the sample crossed a threshold of 10 s.d. above the base line fluorescence. The GAPDH and AML1 standard curves were constructed by plotting the logarithmic value of original concentration of RNA vs the C T value. The AML1 standard curve is shown in Figure  5b . The C T value decreased linearly with the increase of the log amount of RNA. Unknown input amounts of the patient and control samples were calculated from the standard curves. The standard curves and the PCR amplifications of all the patient and control samples were repeated twice in two separate runs. The values obtained for each independent set of analyses were remarkably close for all samples except three, which had to be retested.
AML1 is over-expressed in childhood ALL:
The combined results of both runs showed that the corrected AML1 expression level for the control group ranged from 1.34 to 2.975 (mean = 2.441), whereas for the patient group it ranged from 0.93 to 9.78 (mean = 3.741). Eighteen out of the 41 childhood ALL patients (43.9%) showed corrected AML1 expression levels higher than the estimated 95th percentile of corrected AML1 expression level for the control group (P value Ͻ0.05) ( Figure 6 and Table 2 ). The highest expression levels were seen in patients who had either tandem AML1 copies on der(21) or non-constitutional trisomy 21, with the
Figure 6
Corrected AML1 expression levels in both the control and childhood ALL patient groups. The horizontal dashed line represents the cut-off value of significance, which is the estimated 95th percentile of corrected AML1 expression level in the control group. Eighteen out of the 41 ALL patients (43.9%) showed significantly higher expression levels than the control group (P value Ͻ0.05). (b) Childhood ALL patients carrying either tandem AML1 copies on der(21) or non-constitutional trisomy 21; (᭺) patients carrying neither tandem AML1 copies on der(21) nor non-constitutional trisomy 21; (᭛) control group. exception of patient Nos 4, 17 and 28. The high levels of AML1 expression did not show any obvious correlation with the clinical data, TLC, and immunophenotype at diagnosis. However, we should point out that because of socio-economic reasons, it is not possible at the present time to have further clinical follow-up of these patients.
Discussion
In the present study, we report the immunophenotypic, cytogenetic, and RT-PCR results of 41 newly diagnosed Egyptian childhood ALL patients. The immunophenotypic analysis revealed that 27 patients had B-lineage ALL (65.8%) and 14 patients had T cell ALL (34.2%). The frequency of T cell ALL in our patients is significantly higher than that reported for western countries. 33 However, similar frequencies were observed for patients in Greece, Israel and Bulgaria, [40] [41] [42] suggesting that geographical factors could be implicated in the pathogenesis of this disease.
Translocation (12;21)(p13;q22) leading to TEL-AML1 gene fusion is a cryptic abnormality not easily detected with conventional cytogenetics. In the current study we used both RT-PCR and dual-color FISH analyses for the detection of TEL-AML1 fusion. By RT-PCR, six samples (14.6%) were TEL-AML1 positive, two of them were early pre-B ALL, while the remaining four were pre-B ALL. All six cases showed a 269-bp TEL-AML1 product, indicating fusion of TEL exon 5 with AML1 exon 2. Concordant results were observed by FISH analysis. There is a discrepancy in the frequency of TEL-AML1 fusion in pediatric ALL all over the world. 43 The frequency in the present study is comparable to that reported for western countries among the B-lineage group (22.2%), [5] [6] [7] but lower among the whole group of pediatric ALL patients (14.6%), possibly due to the higher frequency of T cell ALL in our group of patients.
The deletion of one normal TEL allele has been frequently reported in childhood ALL in association with and without TEL-AML1 fusion. [24] [25] [26] Using FISH analysis, we detected seven cases (17.1%) with deletion of one TEL allele, two were T cell ALL, while the other five were B-lineage ALL. Two of these TEL deletion cases also had TEL-AML1 fusion. Here, we also report a novel intragenic deletion of TEL exon 7 (case No. 35), which resulted in an out of frame joining of exon 6 with exon 8. This deletion created a frame-shift and introduced a stop codon just seven codons downstream of the deletion junction and led to loss of translation of the C-terminus that includes the ETS domain. This shorter TEL is presumably unable to bind the DNA. We should point out that no genomic abnormality was detected for TEL by FISH analysis in this case. These results indicate that FISH analysis is not sufficient to determine whether the function of TEL has been compromised in the leukemic cells, and suggest that the number of leukemic patients who have lost TEL function could be higher than previously reported.
The second gene involved in the t(12;21), AML1, is also a very frequent target of chromosomal rearrangements associated with human leukemia. So far, there are 14 chromosomal translocations in which AML1 is involved, as observed by FISH analysis. The breakpoint junctions of three of them were cloned, and molecular analysis showed that in all cases, the translocations led to a fusion gene. 44 However, because of scarce leukemic material, the rest of the reported breakpoints involving AML1 were not cloned. It should be noted that aside from the t(12;21) associated with B-lineage ALL and in which the entire AML1 is fused to TEL, all the other translocations were observed in myeloid leukemias, and they resulted consistently in the disruption of AML1 after the RUNT domain and its fusion to a partner gene. [45] [46] [47] We have identified a new chromosomal translocation that disrupts AML1 and joins it to an unknown partner gene on chromosome band 4q31. This translocation, t(4;21)(q31;q22), is the first one reported where AML1 is rearranged in childhood T cell ALL.
Recent findings of tandem amplification of AML1 in a number of cases of childhood ALL suggest that AML1 overexpression by gene amplification may play an etiologic role in ALL, but it has not been clarified whether the additional copies of AML1 result in enhanced gene expression. [29] [30] [31] To study the expression of AML1 in our patients, we used the real-time quantitative RT-PCR approach. Overall, in 18 out of the 41 childhood ALL cases (43.9%), the expression of AML1 was significantly higher than in the control group. In the majority of these cases, the enhanced expression of AML1 was associated with chromosome 21 cytogenetic and FISH abnormalities, either non-constitutional trisomy 21 (five cases) or tandem copies of the AML1 gene on der(21) (four cases with a percentage of cells showing tandem AML1 copies above the FISH cut-off value and six cases below this value). However, it seems that there are also other mechanisms that result in abnormally high expression of AML1 without obvious AML1 changes by FISH analysis (case Nos 2 and 28). It is possible that in these cases the activity of the promoter itself may be altered. Using PB mononuclear cells as a control is probably not the ideal reference against which we can compare the AML1 expression level seen in immature B and T cell leukemic blasts, however, we should point out that obtaining a sample of immature B or T cells from a normal healthy child is practically an impossible task. One could argue that the high expression of AML1 could be the result of comparing leukemic cells to PB mononuclear cells, and could therefore be related to the immature status of the leukemic cells rather than to their malignant nature. However, the following observations would indicate otherwise. First, in contrast to the highly clustered values for the normal controls, we find that the corrected AML1 values for our group of patients are spread over a wide range, with values lower than the lowest control and values as high as four-fold the mean of the control group. Second, the distribution of corrected AML1 values shows two groups; the first group is clustered at a level more or less equal to that of the controls, whereas the second group is spread at a higher level than the controls, and it is this second group that shows AML1 extra copies by FISH. Third, there is no correlation between the corrected AML1 values and the stage of arrest in B cell differentiation of our early pre-B or pre-B patients, not even among the t(12;21) patients.
In conclusion, we believe that our finding of a high level of expression of AML1 gene in childhood ALL could be an important factor contributing to the pathogenesis and progression of the disease, possibly by functionally altering the normal activity of the AML1/CBF␤ complex. One key mechanism for the over-expression seems to be the extra copies of AML1, but other mechanisms are involved. Because we did not sequence the AML1 cDNA in those patients with enhanced AML1 expression, we cannot state that the extra copies of AML1 leads to the over-expression of a normal protein. However, it is intriguing that over-expression of AML1 is observed in childhood ALL, in contrast to haploinsufficiency, which is observed in adult myeloid leukemia. To understand the role of AML1 extra copies and over-expression in pediatric ALL, further studies are required to check AML1 expression at Leukemia the protein level and also to investigate the possibility of a potentially mutated AML1 transcript. Finally, other candidate co-amplified gene(s) residing in the 21q amplicon need to be investigated.
